Fibrocell Science makes board appointment
This article was originally published in Scrip
Fibrocell Science (US), a biotechnology company focused on the development of regenerative fibroblast cell therapy for aesthetic, medical and scientific applications, has appointed Marc Mazur to its board of directors. He is the chairman of the London-based equity hedge fund Elsworthy Capital Management.
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.